NCT01805531 - Satisfaction/Quality of Life With Rivaroxaban in SPAF (Stroke Prevention in Atrial Fibrillation) Indication | Biotech Hunter

Enrollment

411

Participants

Timeline

Start Date

April 30, 2013

Primary Completion Date

January 31, 2015

Study Completion Date

March 31, 2015

Conditions

Atrial Fibrillation

Interventions

DRUG

Rivaroxaban (Xarelto, BAY59-7939)

20 mg po once daily, which is also the recommended maximum dose. In subjects with moderate creatinine clearance (30-49 ml/min), the dose 15 mg once daily is recommended.

Trial Locations (1)

Unknown

Many Locations